Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis [PDF]
Frontiers in ImmunologyNatalizumab, a monoclonal antibody used to treat multiple sclerosis, can undergo Fab-arm exchange (FAE) with endogenous IgG4, resulting in a monovalent form with reduced avidity and presumed lower potency than the parental bivalent form.
Liza M.Y. Gelissen +13 more
doaj +2 more sources
Drugs of Today, 2006 Medical therapeutics has entered a new and exciting era with the development of biological agents that target specific sites. In the studies performed to date, natalizumab, a humanized monoclonal antibody to alpha4 integrin, when administered intravenously at monthly intervals, appeared to be highly beneficial with respect to decreasing both relapse ...
openaire +3 more sources
Use of subcutaneous natalizumab in routine care – Final results of a non-interventional, observational study (SISTER) in Germany and Austria [PDF]
Therapeutic Advances in Neurological DisordersBackground Natalizumab is a disease-modifying therapy for patients with relapsing-remitting multiple sclerosis (RRMS). In addition to its original intravenous (IV) formulation, a subcutaneous (SC) route of administration (RoA) was approved in 2021 ...
Ralf Gold +9 more
doaj +2 more sources
Liver Endothelia Orchestrate MASH‐Associated Macrophage Zonation Through FSTL1‐ITGA4 Axis [PDF]
Advanced Science, Volume 13, Issue 54, 28 September 2026.Liver inflammation in MASH fundamentally hinges on the newly defined Kit/STAT2/FSTL1/ITGA4 axis. Declining endothelial Kit collapses normal hepatic zonation, driving an aberrant FSTL1 gradient that recruits pathogenic macrophages. Strikingly, targeting FSTL1‐ITGA4 with anti‐VLA4 restores spatial immune homeostasis and halts disease progression ...
Lin Sun +10 more
wiley +2 more sources
Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom [PDF]
Neurology and TherapyIntroduction Tysabri (natalizumab) is a recombinant humanized IgG4 monoclonal antibody for the treatment of adults with highly active relapsing-remitting multiple sclerosis (RRMS). A subcutaneous (SC) formulation administered by healthcare professionals (
Erwin De Cock +5 more
doaj +2 more sources
American Journal of Neuroradiology, 2010 Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
D T, Selewski +4 more
openaire +2 more sources
Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? [PDF]
PLoS ONE, 2017 Progressive multifocal leukoencephalopathy (PML) is one of the major risks of natalizumab therapy. Despite introduction of the currently employed PML risk stratification algorithm, the incidence of natalizumab-associated PML cases is not decreasing.We ...
Julia Krämer +6 more
doaj +1 more source
Piloting home infusions of Tysabri (natalizumab): a randomised crossover trial
International Journal of Integrated Care, 2019 We developed a new model of care for home infusions of natalizumab for people with multiple sclerosis. The new model of care was then tested in a pilot study comparing home infusions of natalizumab with usual care (attendance in an ambulatory care day ...
Tim Schultz +8 more
doaj +1 more source
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. [PDF]
PLoS ONE, 2012 Natalizumab is a recombinant monoclonal antibody raised against integrin alpha-4 (CD49d). It is approved for the treatment of patients with multiple sclerosis (MS), a chronic inflammatory autoimmune disease of the CNS. While having shown high therapeutic
Thomas F Benkert +7 more
doaj +1 more source
Natalizumab para la esclerosis múltiple remitente-recurrente
Neurología, 2011 Resumen: Introducción: Natalizumab es un anticuerpo monoclonal inhibidor de la migración leucocitaria a través de la barrera hematoencefálica, autorizado para el tratamiento de la esclerosis múltiple remitente-recurrente. Objetivo: Realizar una revisión
A. Horga, M. Tintoré
doaj +1 more source